Evaxion Biotech A/S reports results for the quarter ended in September - Earnings Summary

Evaxion A/S

18/11/2022 14:31

* Evaxion Biotech A/S  EVAX.OQ  reported a quarterly
adjusted loss
of 24 cents​​ per share for the quarter ended in September. The
mean expectation of three analysts for the quarter was for a
loss of 27 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Evaxion Biotech A/S's reported EPS for the quarter was a
loss
of 24 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Evaxion Biotech A/S shares had fallen by 12.2% this
quarter and
lost 47.7% so far this year.
    * The company reported a quarterly loss of $5.74 million.
    * Wall Street's median 12-month price target for Evaxion
Biotech
A/S is $13.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
18 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.27          -0.24          Beat
 Jun. 30 2022      -0.30          -0.20          Beat
 Mar. 31 2022      -0.33          -0.25          Beat
 Dec. 31 2021      -0.29          -0.39          Missed